Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Cantor Fitzgerald analyst Eric Schmidt reiterates bluebird bio (NASDAQ:BLUE) with a Neutral.
bluebird bio, Inc. (NASDAQ:BLUE) today announced that it received notices (the "notices") on August 20, 2024 from The N...
B of A Securities analyst Jason Gerberry maintains bluebird bio (NASDAQ:BLUE) with a Buy and lowers the price target from $4...
RBC Capital analyst Luca Issi reiterates bluebird bio (NASDAQ:BLUE) with a Sector Perform and maintains $4 price target.
Barclays analyst Gena Wang maintains bluebird bio (NASDAQ:BLUE) with a Overweight and lowers the price target from $8 to $4.
Baird analyst Jack Allen maintains bluebird bio (NASDAQ:BLUE) with a Outperform and lowers the price target from $7 to $6.
JP Morgan analyst Eric Joseph downgrades bluebird bio (NASDAQ:BLUE) from Overweight to Neutral.
